![](https://justcarehealth.com/wp-content/uploads/2022/12/image-27.png)
A small randomized trial demonstrated that novel maintenance immunotherapy(VIGIL) provided durable disease control in homologous repair proficient (HRP) ovarian cancer.
A small randomized trial demonstrated that novel maintenance immunotherapy(VIGIL) provided durable disease control in homologous repair proficient (HRP) ovarian cancer.